Therapeutic Drug Monitoring of Voriconazole in Children
暂无分享,去创建一个
[1] A. Warris,et al. Impact of Therapeutic Drug Monitoring of Voriconazole in a Pediatric Population , 2011, The Pediatric infectious disease journal.
[2] W. Haefeli,et al. Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring , 2011, Therapeutic drug monitoring.
[3] R. Guillemain,et al. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. , 2010, Medical mycology.
[4] S. Goutelle,et al. Oral voriconazole dose in children: one size does not fit all. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] S. Eymard-Duvernay,et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[6] D. Marriott,et al. Voriconazole concentrations and outcome of invasive fungal infections. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] H. Shimada,et al. Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age , 2010, Pediatric blood & cancer.
[8] D. Niederwieser,et al. Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients , 2010, Antimicrobial Agents and Chemotherapy.
[9] T. Patterson,et al. Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir. , 2010, Medical mycology.
[10] M. Xavier,et al. Voriconazole therapeutic drug monitoring: focus on safety , 2010, Expert opinion on drug safety.
[11] J. Ibrahim,et al. In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3 , 2010, Drug Metabolism and Disposition.
[12] R. Jelliffe,et al. Voriconazole pharmacokinetics and pharmacodynamics in children. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[14] M. Loriot,et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[15] M. Kurokawa,et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders , 2009, International journal of hematology.
[16] P. Annaert,et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. , 2009, The Journal of antimicrobial chemotherapy.
[17] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Mats O. Karlsson,et al. Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.
[19] P. Hoogerbrugge,et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. , 2008, Therapeutic drug monitoring.
[20] D. Touw,et al. International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations , 2008, Antimicrobial Agents and Chemotherapy.
[21] A. Pakyz,et al. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma. , 2008, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.
[22] J. Donnelly,et al. Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.
[23] J. Gea-Banacloche,et al. Hallucinations during voriconazole therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] R. Preiss,et al. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[25] W. Peetermans,et al. Aggressive Cutaneous Squamous Cell Carcinoma Associated with Prolonged Voriconazole Therapy in a Renal Transplant Patient , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] Hikaru Kobayashi,et al. Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study. , 2008, Chemical & pharmaceutical bulletin.
[27] D. Denning,et al. Voriconazole plasma monitoring , 2008, Archives of Disease in Childhood.
[28] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] R. Lewis. What is the "therapeutic range" for voriconazole? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] A. Dasgupta. Introduction to Therapeutic Drug Monitoring , 2008 .
[32] J. Kosterink,et al. High-dose voriconazole in a critically ill pediatric patient with neuroblastoma. , 2008, The Pediatric Infectious Disease Journal.
[33] F. Boakye-Agyeman,et al. Measurement of voriconazole in serum and plasma. , 2007, Clinical biochemistry.
[34] D. Kontoyiannis,et al. Random plasma concentrations of voriconazole decline over time. , 2007, The Journal of infection.
[35] W. Vogel,et al. Altered Pharmacokinetics of Voriconazole in a Patient with Liver Cirrhosis , 2007, Antimicrobial Agents and Chemotherapy.
[36] D. Hillaire‐buys,et al. Adverse Effects of Voriconazole: Analysis of the French Pharmacovigilance Database , 2007, The Annals of pharmacotherapy.
[37] A. Mejias,et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. , 2007, The Pediatric infectious disease journal.
[38] J. Mehta,et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.
[39] E. Jerome. Compendium of pharmaceuticals and specialties : the Canadian drug reference for health professionals , 2007 .
[40] K. Sepkowitz,et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] D. Schaer,et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.
[42] T. Buclin,et al. Variability of Voriconazole Plasma Levels Measured by New High-Performance Liquid Chromatography and Bioassay Methods , 2006, Antimicrobial Agents and Chemotherapy.
[43] W. Haefeli,et al. Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis , 2006, Antimicrobial Agents and Chemotherapy.
[44] Lauren A. Destino,et al. Annals of Clinical Microbiology and Antimicrobials Open Access Severe Osteomyelitis Caused by Myceliophthora Thermophila after a Pitchfork Injury , 2022 .
[45] J. Kuchta,et al. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. , 2006, International journal of antimicrobial agents.
[46] D. Andes,et al. Pharmacology of Systemic Antifungal Agents , 2006 .
[47] R. Herbrecht,et al. Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.
[48] D. Andes,et al. Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.
[49] N. Wood,et al. Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.
[50] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.
[51] R. Jacobs,et al. Intravenous Voriconazole Therapy in a Preterm Infant , 2005, Pharmacotherapy.
[52] J. Mehta,et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.
[53] B. Keevil,et al. Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry , 2004, Therapeutic drug monitoring.
[54] B. Keevil,et al. Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] A. Agrawal,et al. Voriconazole-Induced Musical Hallucinations , 2004, Infection.
[56] W. Haefeli,et al. Voriconazole-induced QT interval prolongation and ventricular tachycardia: a non-concentration-dependent adverse effect. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] R. Herbrecht. Voriconazole: therapeutic review of a new azole antifungal , 2004, Expert review of anti-infective therapy.
[58] M. Karlsson,et al. Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.
[59] Judy E. Kim,et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. , 2004, Archives of ophthalmology.
[60] N. Wood,et al. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.
[61] N. Wood,et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. , 2003, British journal of clinical pharmacology.
[62] N. Wood,et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.
[63] N. Wood,et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. , 2003, British journal of clinical pharmacology.
[64] N. Wood,et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. , 2003, British journal of clinical pharmacology.
[65] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[66] S. Roffey,et al. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] M. Rinaldi,et al. Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.
[68] N. Wood,et al. Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] D. Andes. In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis , 2003, Antimicrobial Agents and Chemotherapy.
[70] C. A. Kauffman,et al. Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] B. Potoski,et al. The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] W. Sponsel,et al. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[73] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[74] L. Dupuis,et al. Therapeutic Drug Monitoring of Lamotrigine , 2002, The Annals of Pharmacotherapy.
[75] H. Lazarus,et al. Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.
[76] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] J. Perfect,et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children , 2002, The Pediatric infectious disease journal.
[78] D. Denning,et al. Muco‐cutaneous retinoid‐effects and facial erythema related to the novel triazole antifungal agent voriconazole , 2001, Clinical and experimental dermatology.
[79] J. Lavandera,et al. Optimization of the separation of a group of antifungals by capillary zone electrophoresis. , 2001, Journal of chromatography. A.
[80] A. Bernard,et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] L. See,et al. Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe CandidaInfections Treated with Fluconazole , 2000, Antimicrobial Agents and Chemotherapy.
[82] J. Peacock,et al. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[83] Russell E. Lewis,et al. Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology , 2000, Antimicrobial Agents and Chemotherapy.
[84] J. Rodríguez-Tudela,et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] M. Rinaldi,et al. Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma , 2000, Antimicrobial Agents and Chemotherapy.
[86] P. E. Verweij,et al. Voriconazole (Pfizer ltd). , 1999, IDrugs : the investigational drugs journal.
[87] D. Andes,et al. Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model , 1999, Antimicrobial Agents and Chemotherapy.
[88] D. Stopher,et al. A rapid HPLC assay for voriconazole in human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.
[89] Michael H. Miller,et al. Pharmacodynamics of Fluconazole in a Murine Model of Systemic Candidiasis , 1998, Antimicrobial Agents and Chemotherapy.
[90] M. H. Ensom,et al. Clinical Pharmacokinetics in the 21st Century , 1998, Clinical pharmacokinetics.
[91] E. Thiel,et al. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia , 1997, British journal of haematology.
[92] D. Stopher,et al. Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[93] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[94] J. M. Byers. What Is a Therapeutic Range , 1980 .